Plain-English translation of NCT07017946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing , a capsule containing donor microbiome material, to see if it can help people with ALS. Researchers believe changes in gut bacteria may play a role in ALS progression, so this treatment aims to restore a healthier microbiome. The study will track whether the medication is safe and whether it affects how quickly the disease progresses.
ALS is a fast-moving disease with few treatment options. Recent research suggests that changes in gut bacteria may influence disease progression, making microbiome restoration a promising new avenue to explore for slowing ALS.
You likely qualify if…
You likely don't qualify if…
Over 24 weeks, you will visit the clinic in person at weeks 0, 4, 12, and 24, with phone check-ins at weeks 1, 8, 16, and 20. Before starting the treatment, you'll take antibiotics for about 2 weeks to clear your gut. Then you'll take the medication capsules daily—two per day for the first 3 days, then one per day for 8 weeks. Throughout the study, you'll provide blood and stool samples so researchers can measure changes in nerve markers and analyze your microbiome.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States